OA04-02. Strong HIV-specific CD4 and CD8 T-lymphocyte proliferation in HIV-1 DNA prime/modified vaccinia virus Ankara (MVA) heterologous boost vaccinees

by Biberfeld G, Sandström E, Gaines H, Marovich M, Wahren B, Karlén K, Aboud S, Nilsson C, Godoy-Ramirez K
Published 2009-10-01

Antibody-mediated inhibition of HIV-1 elicited by HIV-I DNA priming and boosting with heterologous HIV-1 recombinant MVA in healthy Tanzanian adults

by Joachim A, Nilsson C, Aboud S, Lyamuya EF, Robb M, Marovich M, Ochsenbauer C, Wahren B, Sandström E, Biberfeld G, Ferrari G, Polonis VR
Published 2012-09-01

P19-20. Allogeneic stimulation of the anti-viral APOBEC3G in human CD4+ T cells and prevention of SHIV infectivity in macaques immunized with HLA antigens

by Yang G, Babaahmady K, Seidl T, Pido-Lopez J, Vaughan R, Shaw O, Schuitemaker H, Bunnik E, Bergmeier LA, Singh M, Wyatt R, Scholler J, Whittall T, Wang Y, Thorstensson R, Biberfeld G, Lehner T
Published 2009-10-01

P19-08. Immunisation with recombinant HLA class I and II, HIV-1gp140 and SIVp27 antigens elicits protection against SHIV-SF162P4 infection in rhesus macaques

by Schuitemaker H, Wyatt RT, Shao Y, Yang G, Vaughan R, Singh M, Bergmeier LA, Wang Y, Seidl T, Shaw O, Pihlainen E, Bergqvist L, Wehlin L, Bunnik E, Jansson M, Schøller J, Mörner A, Biberfeld G, Thorstensson R, Lehner T
Published 2009-10-01

P14-14 LB. A low dose of multigene, multiclade HIV DNA given intradermally induces strong and broad immune responses after boosting with heterologous HIV MVA

by Wahren B, Moss B, Earl P, Michael N, Marovich M, Robb M, Brave A, Hejdeman B, Stout R, Mwanyika L, Mbwana J, Janabi M, Lyamuya E, Aris EA, Moshiro C, Buma D, Francis J, Nilsson C, Aboud S, Bakari M, Biberfeld G, Pallangyo K, Mhalu F, Sandstrom E
Published 2009-10-01

Preferential targeting of conserved Gag regions after vaccination with a heterologous DNA prime Modified Vaccinia Ankara boost HIV vaccine regime

by Bauer A, Podola L, Haule A, Sudi L, Nilsson C, Mann P, Missanga M, Kaluwa B, Maboko L, Lueer C, Mwakatima M, Aboud S, Bakari M, Currier J, Robb M, Joseph S, McCormack S, Lyamuya E, Wahren B, Sandström E, Biberfeld G, Hoelscher M, Kroidl A, Geldmacher C
Published 2012-09-01

Breadth, phenotype and functionality of Gag-specific T cell responses induced by a heterologous DNA/MVA prime-boost HIV-1 vaccine regimen

by Podola L, Bauer A, Haule A, Sudi L, Nilsson C, Godoy-Ramirez K, Mann P, Missanga M, Kaluwa B, Maboko L, Lueer C, Mwakatima M, Aboud S, Bakari M, Currier J, Robb M, McCormack S, Joseph S, Lyamuya E, Hoelscher M, Wahren B, Sandström E, Biberfeld G, Geldmacher C, Kroidl A
Published 2012-09-01

Priming with a “simplified regimen” of HIV-1 DNA vaccine is as good as a “standard regimen” when boosted with heterologous HIV-1 MVA vaccine

by Munseri P, Kroidl A, Nilsson C, Moshiro C, Aboud S, Joachim A, Geldmacher C, Aris E, Buma D, Lyamuya E, Gotch F, Godoy-Ramirez K, Pallangyo K, Maboko L, Marovich M, Robb M, Hoelscher M, Janabi M, Mann P, Joseph S, Mfinanga S, Stoehr W, Mhalu F, Wahren B, Biberfeld G, McCormack S, Sandstrom E, Bakari M
Published 2012-09-01